Atezolizumab

Patent Expiry and the Need for New Therapeutic Strategies Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, August 18, 2025 / EINPresswire.com / -- PD-1/PD-L1 inhibitors such as Keytruda, Opdivo, Tecentriq, Imfinzi, and Libtayo have been standard-of-care treatments for multiple cancer indications since their approvals beginning in 2014. Key U.S. patents for these agents are projected to expire between 2028 and 2030. While the introduction of biosimilars may improve treatment accessibility, it also highlights the need for new therapeutic strategies—particularly combination regimens—that can deliver improved clinical outcomes and address patient populations with suboptimal responses to current therapies. Pharmaceutical development efforts are increasingly focused on combination approaches that can enhance efficacy, expand the range of responsive tumor types, and maintain relevance in an evolving treatment landscape. Scientific Rationale and Differentiation of IBA101 IBA101 is a next-generation CD47-blocking monoclonal antibody engineered to avoid binding to red blood cells and platelets, thereby reducing the risk of severe anemia and thrombocytopenia observed with earlier CD47 inhibitors. Mechanistically, IBA101 promotes innate immune activation, particularly macrophage-mediated phagocytosis of tumor cells. This leads to increased tumor antigen release and presentation, priming the adaptive immune system and generating tumor-specific T-cell responses. In contrast, PD-1/PD-L1 blockade primarily amplifies tumor-reactive T cells that are already present within the patient’s immune repertoire, enabling them to attack tumor cells. Although effective, this approach can be limited by tumor clonal heterogeneity: not all malignant clones express the same target antigens, allowing some tumor subpopulations to evade immune clearance and potentially cause relapse. By enhancing macrophage-mediated tumor antigen presentation, IBA101 has the potential to stimulate de novoT-cell responses against newly exposed tumor antigens. This continuous induction of T-cell immunity against evolving antigenic targets may help track and eliminate emerging tumor variants, reducing immune escape and potentially extending remission. Synergy with PD-1/PD-L1 Blockade The immunologic complementarity between CD47 blockade and PD-1/PD-L1 inhibition provides a strong rationale for combination therapy:  Upstream activation: IBA101 enhances antigen presentation and primes T cells through innate immune pathways.  Downstream release: PD-1/PD-L1 inhibitors relieve inhibitory signaling in these activated T cells, enabling sustained anti-tumor activity. Preclinical studies have shown that IBA101 combined with PD-1 blockade produces synergistic anti-tumor effects with a favorable safety profile. Planned clinical trials aim to determine whether this combination can improve objective response rates, depth of response, and durability compared to PD-1/PD-L1 monotherapy, particularly in patient groups with limited benefit from existing therapies. Outlook Ongoing research will clarify whether combining IBA101 with PD-1/PD-L1 blockade can address the challenge of tumor heterogeneity and expand the therapeutic reach of checkpoint inhibitors. These investigations are intended to generate robust clinical evidence to guide future treatment strategies in oncology. About Liminatus Pharma Liminatus Pharma (Nasdaq: LIMN) is a preclinical-stage immuno-oncology company advancing IBA101 toward best-in-human trials. Building on over a decade of CD47 research and lessons learned from industry setbacks, Liminatus’s mission is to develop next-generation immunotherapies that restore immune balance—bridging innate and adaptive immunity to drive safer, more durable anti-tumor responses. Forward-Looking Statements Cautionary Note Regarding Forward-Looking Statements Statements in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that Liminatus Pharma, Inc. expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words "will," "may," "believes," "anticipates," "thinks," "expects," "estimates," "plans," "intends" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management's assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. For more information, please contact: Chris Kim, Chief Executive Officer info@liminatuspharma.com 213-273-5453 www.liminatuspharma.com Chris Kim Liminatus Pharma, Inc +1 213-273-5453 Chris@liminatus.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with same title Aug. 14, 2025 -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100’s synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor. LIXTE’s Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases LIXTE’s strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform’s potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. The content above comes from the network. if any infringement, please contact us to modify.